{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T01:58:54Z","timestamp":1780883934347,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"DOI":"10.1186\/s13011-026-00730-9","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:47:11Z","timestamp":1776358031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A hospital-based multi-centric observational study to explore the prevalence and correlates of non-medical use and dependence of pregabalin among the patients with substance use disorder in Punjab &amp; Chandigarh"],"prefix":"10.1186","volume":"21","author":[{"given":"Jitender","family":"Aneja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeru","family":"Bala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Domun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Bangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Udey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawahar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"4","key":"730_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4997\/jrcpe.2017.402","volume":"47","author":"EE Morrison","year":"2017","unstructured":"Morrison EE, Sandilands EA, Webb DJ. Gabapentin and pregabalin: do the benefits outweigh the harms? J R Coll Physicians Edinb. 2017;47(4):310\u20133.","journal-title":"J R Coll Physicians Edinb"},{"issue":"12","key":"730_CR2","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","volume":"43","author":"S H\u00e4gg","year":"2020","unstructured":"H\u00e4gg S, J\u00f6nsson AK, Ahlner J. Current Evidence on Abuse and Misuse of Gabapentinoids. Drug Saf. 2020;43(12):1235\u201354.","journal-title":"Drug Saf"},{"issue":"10","key":"730_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Brockbrader","year":"2010","unstructured":"Brockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A Comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"730_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","volume":"30","author":"O Schjerning","year":"2016","unstructured":"Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse potential of pregabalin: A systematic review. CNS Drugs. 2016;30(1):9\u201325.","journal-title":"CNS Drugs"},{"issue":"3","key":"730_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejpain.2010.07.011","volume":"15","author":"K Rutten","year":"2011","unstructured":"Rutten K, De Vry J, Robens A, Tzschentke TM, Van Der Kam EL. Dissociation of rewarding, anti-aversive and anti-nociceptive effects of different classes of anti-nociceptives in the rat. Eur J Pain. 2011;15(3):299\u2013305.","journal-title":"Eur J Pain"},{"issue":"4","key":"730_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ejp.1161","volume":"22","author":"SA Bura","year":"2018","unstructured":"Bura SA, Caba\u00f1ero D, Maldonado R. Operant self-administration of pregabalin in a mouse model of neuropathic pain. Eur J Pain. 2018;22(4):763\u201373.","journal-title":"Eur J Pain"},{"issue":"7","key":"730_CR7","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00213-019-05198-z","volume":"236","author":"B Coutens","year":"2019","unstructured":"Coutens B, Mouledous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin A, et al. Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse. Psychopharmacology. 2019;236(7):2069\u201382.","journal-title":"Psychopharmacology"},{"key":"730_CR8","unstructured":"National Institute on Drug Abuse; U.S. Department of Health and Human Services; National Institute of Health. Research Report Series - Prescription drugs: Abuse and addiction. NIH Publication Number 11\u20134881. Revised October 2011. Available from: http:\/\/www.drugabuse.gov\/sites\/default\/files\/rrprescription.pdf"},{"key":"730_CR9","volume-title":"The ICD-10 classification of mental and behavioural disorders","author":"World Health Organization","year":"1993","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization; 1993."},{"key":"730_CR10","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.drugalcdep.2019.107709","volume":"206","author":"R Vickers-Smith","year":"2020","unstructured":"Vickers-Smith R, Sun J, Charnigo RJ, Lofwall MR, Walsh SL, Havens JR. Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Drug Alcohol Depend. 2020;206:107709.","journal-title":"Drug Alcohol Depend"},{"key":"730_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.sapharm.2018.06.018","volume":"15","author":"KE Evoy","year":"2019","unstructured":"Evoy KE, Covvery JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food and Drug Administration Adverese Events Reporting System (FAERS). Res Soc Adm Pharm. 2019;15:953\u20138.","journal-title":"Res Soc Adm Pharm"},{"issue":"7","key":"730_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","volume":"30","author":"S Chiappini","year":"2016","unstructured":"Chiappini S, Schifano F. A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency\u2019s \u2018Suspected Adverse Drug Reactions\u2019 Database. CNS Drugs. 2016;30(7):647\u201354.","journal-title":"CNS Drugs"},{"issue":"9","key":"730_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40261-016-0421-z","volume":"36","author":"JB Bossard","year":"2016","unstructured":"Bossard JB, Pont\u00e9 C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. Clin Drug Investig. 2016;36(9):735\u201342.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"730_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","volume":"66","author":"S Schwan","year":"2010","unstructured":"Schwan S, Sundstroom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin\u2013results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66(9):947\u201353.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"730_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","volume":"69","author":"M Gahr","year":"2013","unstructured":"Gahr M, Freudenmann RW, Hiemke C, K\u00f6lle MA, Sch\u00f6nfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69(6):1335\u201342.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"730_CR16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s11469-017-9813-4","volume":"16","author":"A Al-Husseini","year":"2018","unstructured":"Al-Husseini A, Wazaify M, Van Hout MC. Pregabalin Misuse and Abuse in Jordan: a Qualitative Study of User Experiences. Int J Ment Health Addict. 2018;16(3):642\u201354.","journal-title":"Int J Ment Health Addict"},{"key":"730_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.4103\/psychiatry.IndianJPsychiatry_475_19","volume":"62","author":"A Singh","year":"2020","unstructured":"Singh A, Sidana A, Agrawal A, Arun P. Pregabalin dependence. Indian J Psychiatry. 2020;62:738\u20139.","journal-title":"Indian J Psychiatry"},{"issue":"2","key":"730_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/jmhhb.jmhhb_167_21","volume":"26","author":"A Ghosh","year":"2021","unstructured":"Ghosh A, Prasad S, Basu A, Basu D. Two More Cases of Pregabalin Dependence: The Pandora\u2019s Box is Open and Needs Serious Attention. J Ment Health Hum Behav. 2021;26(2):174\u20135.","journal-title":"J Ment Health Hum Behav"},{"issue":"S1","key":"730_CR19","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.4103\/0972-6748.328855","volume":"30","author":"S Sahu","year":"2021","unstructured":"Sahu S, Kumar S, Chaudhury S, Saldanha D. A case of pregabalin addiction. Ind Psychiatry J. 2021;30(S1):S352\u20133.","journal-title":"Ind Psychiatry J"},{"issue":"2","key":"730_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/02537176221122389","volume":"45","author":"J Aneja","year":"2023","unstructured":"Aneja J, Singh J. Pregabalin Use\/Misuse: A Source of Consternation in Western Punjab. Indian J Psychol Med. 2023;45(2):206\u20137.","journal-title":"Indian J Psychol Med"},{"issue":"8","key":"730_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_307_24","volume":"66","author":"A Ghosh","year":"2024","unstructured":"Ghosh A, Shukla S, Dhankar M, Naik SS, Subodh BN, Basu D. Understanding pregabalin misuse and dependence: Insights from a North Indian addiction treatment center. Indian J Psychiatry. 2024;66(8):723\u20138.","journal-title":"Indian J Psychiatry"},{"key":"730_CR22","doi-asserted-by":"publisher","first-page":"109400","DOI":"10.1016\/j.drugalcdep.2022.109400","volume":"234","author":"MS Ellis","year":"2022","unstructured":"Ellis MS, Buttram ME, Kasper ZA. Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder. Drug Alcohol Depend. 2022;234:109400.","journal-title":"Drug Alcohol Depend"},{"key":"730_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1046\/j.1360-0443.2002.00185.x","volume":"97","author":"WHO ASSIST Working Group","year":"2002","unstructured":"WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, Reliability and Feasibility. Addiction. 2002;97:1183\u201394.","journal-title":"Addiction"},{"key":"730_CR24","volume-title":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Guidelines for use in Primary Care. Draft Version 1.1 for Field Testing","author":"S Henry-Edwards","year":"2003","unstructured":"Henry-Edwards S, Humeniuk RE, Ali RL, Poznyak V, Monteiro M. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Guidelines for use in Primary Care. Draft Version 1.1 for Field Testing. Geneva: World Health Organization; 2003."},{"issue":"4","key":"730_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11096-020-01217-8","volume":"43","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Covvey JR, Peckham AM, Reveles KR. Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. Int J Clin Pharm. 2021;43(4):1055\u201364.","journal-title":"Int J Clin Pharm"},{"issue":"4","key":"730_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","volume":"77","author":"KE Evoy","year":"2017","unstructured":"Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403\u201326.","journal-title":"Drugs"},{"issue":"1","key":"730_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","volume":"81","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81(1):125\u201356.","journal-title":"Drugs"},{"key":"730_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jsat.2019.12.007","volume":"110","author":"MD Stein","year":"2020","unstructured":"Stein MD, Kenney SR, Anderson BJ, Conti MT, Bailey GL. Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification. J Subst Abuse Treat. 2020;110:37\u201341.","journal-title":"J Subst Abuse Treat"},{"key":"730_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40263-017-0467-3","volume":"31","author":"BJ Snellgrove","year":"2017","unstructured":"Snellgrove BJ, Steinert T, Jaeger S. Pregabalin use among users of illicit drugs: a cross-sectional survey in Southern Germany. CNS Drugs. 2017;31:891\u20138.","journal-title":"CNS Drugs"},{"issue":"4","key":"730_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s11126-016-9421-7","volume":"87","author":"L Bastiaens","year":"2016","unstructured":"Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q. 2016;87(4):763\u20137.","journal-title":"Psychiatr Q"},{"key":"730_CR31","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3389\/fpsyt.2019.01022","volume":"10","author":"M Lancia","year":"2020","unstructured":"Lancia M, Gambelunghe A, Gili A, Bacci M, Aroni K, Gambelunghe C. Pregabalin Abuse in Combination With Other Drugs: Monitoring Among Methadone Patients. Front Psychiatry. 2020;10:1022.","journal-title":"Front Psychiatry"},{"issue":"6","key":"730_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/add.14412","volume":"114","author":"R Cairns","year":"2019","unstructured":"Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction. 2019;114(6):1026\u201334.","journal-title":"Addiction"},{"issue":"1","key":"730_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-016-0062-5","volume":"11","author":"H Alblooshi","year":"2016","unstructured":"Alblooshi H, Hulse GK, El Kashef A, Al Hashmi H, Shawky M, Al Ghaferi H, et al. The pattern of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation Centre cohort study. Subst Abuse Treat Prev Policy. 2016;11(1):1\u201311.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"730_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/ajad.12159","volume":"24","author":"T Wilens","year":"2015","unstructured":"Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24(2):173\u20137.","journal-title":"Am J Addict"},{"issue":"3","key":"730_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000355268","volume":"20","author":"CRW Baird","year":"2014","unstructured":"Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: A survey among substance misusers. Eur Addict Res. 2014;20(3):115\u20138.","journal-title":"Eur Addict Res"},{"issue":"2","key":"730_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5694\/mja2.12036","volume":"210","author":"R Crossin","year":"2019","unstructured":"Crossin R, Scott D, Arunogiri S, Smith K, Dietze PM, Lubman DI. Pregabalin misuse-related ambulance attendances in Victoria, 2012\u20132017: characteristics of patients and attendances. Med J Aust. 2019;210(2):75\u20139.","journal-title":"Med J Aust"},{"key":"730_CR37","doi-asserted-by":"publisher","first-page":"l2147","DOI":"10.1136\/bmj.l2147","volume":"365","author":"Y Molero","year":"2019","unstructured":"Molero Y, Larsson H, D\u2019Onofrio BM, Sharp DJ, Fazel S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: Population based cohort study in Sweden. BMJ. 2019;365:l2147.","journal-title":"BMJ"},{"issue":"6","key":"730_CR38","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/bcp.13892","volume":"85","author":"D Driot","year":"2019","unstructured":"Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85(6):1260\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"730_CR39","first-page":"700","volume":"16","author":"AA Alkhalaf","year":"2021","unstructured":"Alkhalaf AA, Bukhari RA, Alshehri EA, Alshehri SO, Badr AF. Abuse liability of gabapentin in the Saudi population after the pregabalin restriction: A cross-sectional study. J Taibah Univ Med Sci. 2021;16(5):700\u20135.","journal-title":"J Taibah Univ Med Sci"},{"issue":"10","key":"730_CR40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/pds.4230","volume":"26","author":"ME Buttram","year":"2017","unstructured":"Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002\u20132015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf. 2017;26(10):1083\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"730_CR41","first-page":"1","volume":"22","author":"A Chatterjee","year":"2019","unstructured":"Chatterjee A, Lopez D, Ramkellawan S, Brown R, Smith K, Gaeta JM, et al. That\u2019s what we call the cocktail: non-opioid medication and supplement misuse among opioid users. Subst Abus. 2019;22:1\u20138.","journal-title":"Subst Abus"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-026-00730-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-026-00730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T01:29:02Z","timestamp":1780882142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13011-026-00730-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1186\/s13011-026-00730-9","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was approved by Institutional Ethics Committee vide IEC\/AIIMS\/BTI\/396, dated 05-08-2023. A written signed informed consent was obtained as per the WHO Guidelines and the study followed Good Clinical Practice Guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have consented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}